Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma

DGP van Ijzendoorn, Stefan Sleijfer, H Gelderblom, Ferry Eskens, Arno van Leenders, K Szuhai, J Bovee

Research output: Contribution to journal › Article › Academic › peer-review

33 Citations (Scopus)

Research programs

@article{67d2c204d86e49c5a1bcdce0c639f974,

title = "Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma",

author = "{van Ijzendoorn}, DGP and Stefan Sleijfer and H Gelderblom and Ferry Eskens and {van Leenders}, Arno and K Szuhai and J Bovee",

year = "2018",

doi = "10.1158/1078-0432.ccr-17-3512",

language = "Undefined/Unknown",

volume = "24",

pages = "2678--2687",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "11",

}

TY - JOUR

T1 - Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma

AU - van Ijzendoorn, DGP

AU - Sleijfer, Stefan

AU - Gelderblom, H

AU - Eskens, Ferry

AU - van Leenders, Arno

AU - Szuhai, K

AU - Bovee, J

PY - 2018

Y1 - 2018

U2 - 10.1158/1078-0432.ccr-17-3512

DO - 10.1158/1078-0432.ccr-17-3512

M3 - Article

SN - 1078-0432

VL - 24

SP - 2678

EP - 2687

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 11

ER -